BACKGROUND: [18F]-fluorodeoxyglucose with positron-emission tomography (PET) and computed tomography (CT) scans were used to assess morphological and metabolic tumour response after chemotherapy in metastatic colorectal cancer. PATIENTS AND METHODS: Twenty-five patients were evaluated after 4 courses of chemotherapy (+/-target therapy), and among them 20 patients after 2 courses. Response Evaluation Criteria In Solid Tumors (RECIST) and European Organisazion for Research and Treatment of Cancer (EORTC) criteria were used to evaluate CT and PET respectively. RESULTS: Discrepancies between the two procedures were noted after 4 courses of chemotherapy in patient-based analysis. Two morphologically complete responses (CR) were correlated with metabolic response. Seven morphological partial responses (PR) were evaluated as 3 metabolic PR, 2 CR and 1 progressive disease (PD). Seventeen cases of morphologically stable disease (SD) were evaluated as 3 metabolic CR, 13 PR and 1 PD. These discrepancies were confirmed in lesion-based analysis. Perfect concordance was noted between metabolic responses obtained after 2 and 4 cycles. CONCLUSION: Morphological and metabolic imaging does not permit concordant therapeutic assessment in metastatic colorectal cancer.
BACKGROUND:[18F]-fluorodeoxyglucose with positron-emission tomography (PET) and computed tomography (CT) scans were used to assess morphological and metabolic tumour response after chemotherapy in metastatic colorectal cancer. PATIENTS AND METHODS: Twenty-five patients were evaluated after 4 courses of chemotherapy (+/-target therapy), and among them 20 patients after 2 courses. Response Evaluation Criteria In Solid Tumors (RECIST) and European Organisazion for Research and Treatment of Cancer (EORTC) criteria were used to evaluate CT and PET respectively. RESULTS: Discrepancies between the two procedures were noted after 4 courses of chemotherapy in patient-based analysis. Two morphologically complete responses (CR) were correlated with metabolic response. Seven morphological partial responses (PR) were evaluated as 3 metabolic PR, 2 CR and 1 progressive disease (PD). Seventeen cases of morphologically stable disease (SD) were evaluated as 3 metabolic CR, 13 PR and 1 PD. These discrepancies were confirmed in lesion-based analysis. Perfect concordance was noted between metabolic responses obtained after 2 and 4 cycles. CONCLUSION: Morphological and metabolic imaging does not permit concordant therapeutic assessment in metastatic colorectal cancer.
Authors: Elizabeth McKeown; Daniel W Nelson; Eric K Johnson; Justin A Maykel; Alexander Stojadinovic; Aviram Nissan; Itzhak Avital; Björn Ldm Brücher; Scott R Steele Journal: J Cancer Date: 2014-01-01 Impact factor: 4.207
Authors: Keith W H Chiu; Ka-On Lam; H An; Gavin T C Cheung; Johnny K S Lau; Tim-Shing Choy; Victor H F Lee Journal: BMC Cancer Date: 2018-07-31 Impact factor: 4.430
Authors: Safenaz Y El Sherity; Shymaa A Shalaby; Nayera E Hassan; Sahar A El-Masry; Rokia A El-Banna Journal: Open Access Maced J Med Sci Date: 2019-07-27
Authors: B Ma; A D King; L Leung; K Wang; A Poon; W M Ho; F Mo; C M L Chan; A T C Chan; S C C Wong Journal: Ann Oncol Date: 2017-07-01 Impact factor: 32.976
Authors: Erik J van Helden; Otto S Hoekstra; Ronald Boellaard; Chantal Roth; Emma R Mulder; Henk M W Verheul; C Willemien Menke-van der Houven van Oordt Journal: PLoS One Date: 2016-05-19 Impact factor: 3.240
Authors: Brigette Ma; Edwin P Hui; Ann King; Sing F Leung; Michael Km Kam; Frankie Mo; Leung Li; Ki Wang; Herbert Loong; Ashley Wong; Charles Ml Chan; K C Allen Chan; S C Cesar Wong; Y M Dennis Lo; Anthony Tc Chan Journal: Br J Cancer Date: 2018-03-20 Impact factor: 7.640